# Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

> **NCT05968989** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** VRC-FLUMOS0116-00-VP( FLUMos-v2)

## Key facts

- **NCT ID:** NCT05968989
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-09
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05968989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05968989, "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05968989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*